Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
Big pharma companies are already working on an H1N1 swine flu vaccine (Bloomberg) Even as the number of swine flu victims cross 100 in the country, Indian pharmaceutical companies are yet to start manufacturing the much-awaited vaccine as they have not received any purchase commitment from the government. Last week, …
Nina Mehta MUMBAI INDIAN biopharmaceutical companies may face more hurdles in the US. This is on the back of the US Senate Health, Education, Labour and Pensions Committee having approved an amendment that will protect biotech developers from generic competition for 12 years. Though the amendment is yet to be …
Swine flu cases cross 250 mark On a day when the UK warned its people of 65,000 possible swine flu deaths this winter, India said it was doing well to contain the spread of the virus.
To Challenge Intellectual Property Appellate Board Verdict Rejecting Its Patent Plea For Cancer Drug Nina Mehta MUMBAI THE Indian subsidiary of Swiss drugmaker Novartis will challenge a decision by the Intellectual Property Appellate Board (IPAB) that said its cancer drug Glivec was not patentable. Addressing the company
THE government is working to revive a ministerial panel which was set up to finalise a national pharmaceutical policy that has been hotly contested because it seeks to vastly expand the number of drugs under price control. The chemicals and fertilisers ministry has recommended the continuation of the Group of …
Down To Earth filed an RTI application to find out the reason of vaccine shortage in India. The response revealed how a plan to promote private vaccine makers boomeranged. The health ministry was forced to get vaccines illegally from the very public sector manufacturers it suspended last year Shuvam Kumar …
cyrus s poonawalla, chairperson and managing director of Serum Institute of India Ltd, a private vaccine manufacturer, says the vaccine shortage is a mess the government created. Edited excerpts: On self-sufficiency: Except for polio vaccine, we can provide all vaccines required for the Universal Immunization Programme. Whatever orders were placed …
Strengthen public sector The lack of foresight shown by former health minister Anbumani Ramadoss in shutting the public sector without first ensuring alternatives and lack of transparency have put a generation of children at risk. Clearly, the private sector
US-BASED vaccine maker Novavax, that is developing a vaccine for Swine Flu, will conduct a major portion of the clinical trials in India. The trials will be conducted from September in joint collaboration with Ahmedabadbased drug major Cadila Pharmaceuticals. Talking to ET, Rahul Singhvi president & CEO Novavax said:
Guidelines Only Up To Pre-Clinical Stage THE department of biotechnology (DBT) is planning to set up National Biotechnology Regulatory Board to specify and regulate development of drugs and vaccines from natural sources, such as humans, animals or micro-organism, a DBT official said.
Solan: The pharmaceutical hub of Baddi-Barotiwala-Nalagarh has been left high and dry with the budget failing to address any of their grievances, including hike in the excise duty and refund on raw materials. Since the gains of the 2003 Central industrial package had been reduced after two reductions in the …
International studies published last week linked a very widely used synthetic insulin to increased risk of cancer. But millions of Indian diabetes patients who use the drug have reason to be relieved after the US Food and Drug Administration (FDA)
In a setback for Novartis AG, the U.S. Food and Drug Administration asked the Swiss drug maker for more information about its meningitis-vaccine candidate, Menveo, with respect to patients between ages 11 and 55. "The FDA has requested additional information mainly on the manufacturing of the drug, but it didn't …
